search
Back to results

Evaluation of Fluid Infusion With LifeFlow for Patients With Suspected Septic Shock

Primary Purpose

Sepsis, Volume Assessment

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Life Flow
Sponsored by
University of Arizona
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult ED patients ≥ 18 years of age
  • Patients with hypotension (Systolic Blood Pressure (SBP) < 90) mmHg or Mean Arterial Pressure (MAP) < 65 mmHg) and at least one of the following:

    • Temperature > 101 F (38.3 C) or < 96.8 F (36.0 C)
    • Respiratory Rate (RR) > 22 bpm
    • Heart Rate (HR) > 90/min
  • Patients who will be determined by treating emergency physician to receive rapid fluid bolus for hypotension
  • Patients with adequate cardiac windows
  • EF is 35% or greater
  • No increased number of B lines per rib interspace (3 or more) in multiple locations on lung ultrasound

Exclusion Criteria:

  • Heart failure by history or Ejection fraction (EF) < 35 percent on pre-enrollment Point of care (POC) Echocardiogram
  • History of End stage Renal disease
  • History of End stage lung disease
  • Lymphocyte count < 50mm/m3 or Absolute Neutrophil Count < 500
  • Transferred from another facility
  • Requirement for immediate surgery
  • Patients with 14 Gauge catheters or larger
  • Concurrently on vasopressors or inotrope therapy
  • Patients or legally acceptable representatives unable to provide consent
  • Non-sepsis related primary diagnosis including: acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, active gastrointestinal hemorrhage, seizure, drug overdose, burn or trauma, myocardial infarction or active hemorrhage
  • Incarcerated patients
  • Requirement for immediate surgery
  • Known pregnancy

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    No Intervention

    Experimental

    Arm Label

    Control

    LifeFlow group

    Arm Description

    After obtaining the consent, the subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.

    LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.

    Outcomes

    Primary Outcome Measures

    Time of initiation and termination of each fluid bolus administration
    Volume of each fluid bolus administration

    Secondary Outcome Measures

    Length of stay in the Emergency department, Intensive care unit, and total hospital length of stay
    Resolution of abnormal blood pressure (measured at time of arrival, diagnosis and following each fluid bolus)
    Assessment of Adverse effects, including rate of Intravenous fluid infiltration
    Time to administration of antibiotics
    Type of vasopressors used
    Epinephrine vs. Dopamine vs. Dobutamine vs. Norepinephrine
    Number of subjects received a central line
    Need for endotracheal intubation/mechanical ventilation
    Number of ventilator-free days
    Time from initial order to completion of first fluid bolus
    Percent of fluid overload (FO) was calculated using the following formula: [(total fluid intake (L) - total fluid output in liters (L)) / (admission weight in kilograms)*100]
    Peak Fluid overload-defined as the maximum percentage of fluid overload during the first 72 h after initiation of invasive Mechanical Ventilation
    Resolution of abnormal heart rate (measured at time of arrival, diagnosis and following each fluid bolus)
    Time vasopressors are started and discontinued

    Full Information

    First Posted
    September 12, 2018
    Last Updated
    July 11, 2019
    Sponsor
    University of Arizona
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03673891
    Brief Title
    Evaluation of Fluid Infusion With LifeFlow for Patients With Suspected Septic Shock
    Official Title
    Evaluation of Fluid Infusion With LifeFlow for Patients With Suspected Septic Shock
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2019
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Lack of resources
    Study Start Date
    January 1, 2019 (Actual)
    Primary Completion Date
    October 1, 2019 (Anticipated)
    Study Completion Date
    December 31, 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    University of Arizona

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The LifeFlow rapid infusion device is a handheld manually-operated device that has been shown in early trials to increase the rate of bolus fluid infusion up to 3 times the rate of delivery attributed to conventional rapid infusion devices. The device addresses other technical barriers to fluid resuscitation, including reducing complexity and provider fatigue. LifeFlow utilizes standard IV or intraosseous (IO) vascular access devices to quickly and efficiently deliver appropriate volumes of crystalloid fluid to patients during emergent fluid resuscitation. The purpose of this study is to determine if intravenous fluids can be administered more rapidly and efficiently with the use of the LifeFlow rapid infusion device compared to the current standard techniques in adult patients who present to the Emergency Department with septic shock.
    Detailed Description
    Patients with conditions such as septic shock, anaphylaxis, and hypovolemic shock may require rapid fluid administration to restore blood pressure and tissue perfusion. Newly Updated Surviving Sepsis Campaign (SSC) guidelines call for patients with septic shock to receive a 30ml/kg intravenous (IV) fluid challenge within 1 hour of emergency department (ED) arrival, with improved outcomes shown with early fluid infusion. Patients with shock and severe hypotension may require even more rapid fluid treatment, up to 4ml/kg/min. While excess fluid infusion may be associated with harm, early fluid infusion for the reversal of shock can reduce the need for subsequent interventions, ultimately leading to improved patient outcomes. This may be especially true in patients with hypotension, who are at greater risk of death if not treated quickly, as a single episode of hypotension in patients with sepsis is correlated with a significantly increased risk of death. In patients who require IV fluid bolus therapy, technical barriers such as slow infusion rates, technically complex infusion devices, and inadequate nursing resources may lead to delay in fluid administration and inadequate resuscitation. As recommended by the SSC guidelines, patients receiving fluid bolus therapy for septic shock require frequent reassessment of clinical response. With current fluid delivery techniques, the ability to reassess quickly and relate fluid administration directly to markers of hemodynamic improvement is limited. The LifeFlow rapid infusion device is a handheld manually-operated device that has been shown in early trials to increase the rate of bolus fluid infusion up to 3 times the rate of delivery attributed to conventional rapid infusion devices. The device addresses other technical barriers to fluid resuscitation, including reducing complexity and provider fatigue. LifeFlow utilizes standard IV or intraosseous (IO) vascular access devices to quickly and efficiently deliver appropriate volumes of crystalloid fluid to patients during emergent fluid resuscitation. The purpose of this study is to determine if intravenous fluids can be administered more rapidly and efficiently with the use of the LifeFlow rapid infusion device compared to the current standard techniques in adult patients who present to the Emergency Department with septic shock. Primary Hypothesis Intravenous fluids can be administered more rapidly and efficiently with the use of the LifeFlow rapid infusion device compared to the current techniques in patients who present to the ED with hypotension and suspected septic shock Secondary Hypotheses Hypotensive patients receiving intravenous fluids utilizing the LifeFlow infusion device will have more rapid normalization of vital sign parameters (i.e., resolution of hypotension = MAP 65 mmHg or greater), and more rapid improvement in markers of tissue ischemia (i.e., lactate clearance) than patients receiving fluid using other techniques. Based on reduced ICU and hospital length of stay (LOS), the overall cost of treatment will be lower in ED patients receiving early IV fluid resuscitation with LifeFlow comparted to similar patients treated with standard techniques.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Sepsis, Volume Assessment

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Control
    Arm Type
    No Intervention
    Arm Description
    After obtaining the consent, the subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
    Arm Title
    LifeFlow group
    Arm Type
    Experimental
    Arm Description
    LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
    Intervention Type
    Device
    Intervention Name(s)
    Life Flow
    Intervention Description
    LifeFlow device will be used to administer intravenous fluids in this group. LifeFlow is a FDA approved device to administer IV fluids. Subject will have a bedside ultrasound performed by the study investigator after receiving 500 ml of intravenous fluid bolus. The images will be recorded on ultrasound machine hard drive for future review. If the bedside ultrasound findings determine that the subject is not fluid responsive, subjects will be excluded from the study. If the subject is determined to be fluid responsive, the above listed outcome measures will be collected. Ultrasound will be repeated after every 500 ml bolus if the patient continues to receive IV fluids which will be determined by the treating physician. Ultrasound measurements and other parameters listed above will be collected throughout the ED and hospital stay.
    Primary Outcome Measure Information:
    Title
    Time of initiation and termination of each fluid bolus administration
    Time Frame
    Up to 30 days
    Title
    Volume of each fluid bolus administration
    Time Frame
    Up to 30 days
    Secondary Outcome Measure Information:
    Title
    Length of stay in the Emergency department, Intensive care unit, and total hospital length of stay
    Time Frame
    Up to 30 days
    Title
    Resolution of abnormal blood pressure (measured at time of arrival, diagnosis and following each fluid bolus)
    Time Frame
    Up to 30 days
    Title
    Assessment of Adverse effects, including rate of Intravenous fluid infiltration
    Time Frame
    Up to 30 days
    Title
    Time to administration of antibiotics
    Time Frame
    Up to 30 days
    Title
    Type of vasopressors used
    Description
    Epinephrine vs. Dopamine vs. Dobutamine vs. Norepinephrine
    Time Frame
    Up to 30 days
    Title
    Number of subjects received a central line
    Time Frame
    Up to 30 days
    Title
    Need for endotracheal intubation/mechanical ventilation
    Time Frame
    Up to 30 days
    Title
    Number of ventilator-free days
    Time Frame
    Up to 30 days
    Title
    Time from initial order to completion of first fluid bolus
    Time Frame
    Up to 30 days
    Title
    Percent of fluid overload (FO) was calculated using the following formula: [(total fluid intake (L) - total fluid output in liters (L)) / (admission weight in kilograms)*100]
    Time Frame
    Up to 30 days
    Title
    Peak Fluid overload-defined as the maximum percentage of fluid overload during the first 72 h after initiation of invasive Mechanical Ventilation
    Time Frame
    Up to 30 days
    Title
    Resolution of abnormal heart rate (measured at time of arrival, diagnosis and following each fluid bolus)
    Time Frame
    Up to 30 days
    Title
    Time vasopressors are started and discontinued
    Time Frame
    Up to 30 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adult ED patients ≥ 18 years of age Patients with hypotension (Systolic Blood Pressure (SBP) < 90) mmHg or Mean Arterial Pressure (MAP) < 65 mmHg) and at least one of the following: Temperature > 101 F (38.3 C) or < 96.8 F (36.0 C) Respiratory Rate (RR) > 22 bpm Heart Rate (HR) > 90/min Patients who will be determined by treating emergency physician to receive rapid fluid bolus for hypotension Patients with adequate cardiac windows EF is 35% or greater No increased number of B lines per rib interspace (3 or more) in multiple locations on lung ultrasound Exclusion Criteria: Heart failure by history or Ejection fraction (EF) < 35 percent on pre-enrollment Point of care (POC) Echocardiogram History of End stage Renal disease History of End stage lung disease Lymphocyte count < 50mm/m3 or Absolute Neutrophil Count < 500 Transferred from another facility Requirement for immediate surgery Patients with 14 Gauge catheters or larger Concurrently on vasopressors or inotrope therapy Patients or legally acceptable representatives unable to provide consent Non-sepsis related primary diagnosis including: acute cerebral vascular event, acute coronary syndrome, acute pulmonary edema, status asthmaticus, major cardiac arrhythmia, active gastrointestinal hemorrhage, seizure, drug overdose, burn or trauma, myocardial infarction or active hemorrhage Incarcerated patients Requirement for immediate surgery Known pregnancy

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Evaluation of Fluid Infusion With LifeFlow for Patients With Suspected Septic Shock

    We'll reach out to this number within 24 hrs